ClinicalTrials.gg
Active, not recruitingNCT07080775Updated Sep 30, 2026

The Safety,Tolerability, Efficacy of XS411 Cell Injection for the Treatment of Primary Parkinson's Disease

A Phase 1/2 interventional study of human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection in Parkinson's Disease, sponsored by XellSmart Therapeutics (Shanghai) Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by XellSmart Therapeutics (Shanghai) Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Updated Sep 30, 2026Now Active, not recruitingPrimary completion moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.

Enrollment
119th of 211
39 · median 47
Started
2025
with 32 others
Phase 1/2
10 of 279
5 open now
Primary completion
2027-07
later than 96 of 134 live
Registered
218th of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 119th largest by enrollment of the 211 interventional ones that give a count, is one of 33 that started in 2025, is one of 10 in phase 1/2, reaches primary completion later than 96 of the 134 other live ones, and was the 218th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

This Phase I clinical trial is designed to evaluate the safety, tolerability of a single dose of XS411 (derived dopaminergic neural progenitor cell injection) in patients with primary Parkinson's disease.

This Phase II clinical trial is designed to evaluate the safety, tolerability and Efficacy of XS411 (derived dopaminergic neural progenitor cell injection) in patients with Parkinson's disease.

Read the detailed description

This is a phase I clinical study to evaluate the safety and tolerability of human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection (XS411CN) via brain stereotactic transplantation for the treatment of primary Parkinson's disease.

The study adopts a single-arm, open-label, non-randomized dose-escalation design to evaluate the safety, tolerability, and preliminary efficacy of stereotactic brain transplantation of XS411CN in patients with primary Parkinson's disease and explore the optimal recommended dose. 12 to 18 patients with primary Parkinson's disease are planned to be enrolled.

On the day of cell transplantation surgery, the planned dose of XS411CN is transplanted into the bilateral putamen of the subjects by brain stereotactic technology.

After receiving the XS411CN transplantation, the subjects will receive immunosuppressants. All subjects receive standard treatment at the same time.

Each patient receives a safety observation period of 28 days after cell transplantation with XS411CN. This study adopts the traditional "3+3 " dose escalation method. The trial starts with a low dose and the dose will be increased gradually. Each subject will be closely observed for 7 days after surgery, and the dose-limiting toxicity (DLT) events that may occur within 28 days after the first transplant treatment will be evaluated.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged between 50 and 75 years old;
  2. Diagnosed as 'clinically established PD' consistent with MDS clinical Diagnostic Criteria for Parkinson's disease,
  3. A minimum of 5 years since diagnosis;
  4. Hoehn- Yahr score during the off-time is 3 to 4;
  5. The subjects with an average of at least 2.5 hours of "off time" per day;
  6. Stable anti-PD therapy for at least 1 month before screening;
  7. Anti-PD treatment was once effective, but the efficacy has declined significantly or drug-induced motor complications have occurred, affecting the quality of life;
  8. Positive levodopa challenge test (MDS-UPDRS-III score improvement from off- state to on- state > 30%);
  9. At least three months before the first administration, the subject should have completed all vaccinations as recommended by local authorities;
  10. The results of complete blood count meet the following conditions: ≥ 2.0×109 /L, WBC ≥ 4.0×109 /L, ≥ 100×109 /L, HGB ≥ 10g/dL
  11. The patient or his/her legal guardian agree to accept the study and signed the form in writing.

Exclusion criteria

Exclusion Criteria:

  1. Parkinsonian syndrome or secondary Parkinson's disease (Atypical Parkinson's syndrome (Parkinson's plus syndrome, secondary Parkinson's syndrome, hereditary degenerative Parkinson's syndrome);
  2. Patients are in advanced stages of Parkinson's disease and are experiencing severe, disabling peak-dose dyskinesia or biphasic dyskinesia and/or unpredictable or widely fluctuating symptoms;
  3. Severe cognitive impairment (\<24, poor compliance due to dementia, inability to accurately record diaries, and/or inability to sign ;
  4. Those with a history of severe mental illness, or those with severe suicidal tendencies as measured by the Columbia-Suicide Severity Rating Scale (C-SSRS), or those with suicidal ideation in the past 12 months, or those who have attempted suicide in the past 5 years;
  5. Patients with severe brain atrophy, space-occupying lesions, hydrocephalus, cerebral vascular malformations as indicated by head CT/MRI, and those with structural abnormalities that may affect transplantation or increase surgical risks as determined by the investigators;
  6. Currently with active internal bleeding; or arterial puncture at a site that is difficult to stop bleeding within 1 week before screening; or gastrointestinal or urinary bleeding within 3 weeks before screening;
  7. History of striatal or extrapyramidal surgery, including but not limited to deep brain stimulation (DBS) surgery and globus pallidus lesion;
  8. Coagulation abnormalities;
  9. Abnormal liver and kidney function laboratory tests during the screening period;
  10. The patient is currently receiving or has previously received the following treatments:

    • Use of benzodiazepines at a dose level equal to or higher than the recommended dose in Package Insert for more than 4 weeks cumulatively since one month before enrollment, (except for the immunosuppressants to be used in this study), or antipsychotics within 3 months before treatment;
    • Use of botulinum toxin, phenol, subarachnoid baclofen injection, or interventional treatment for dystonia or spasticity within 6 months before treatment;
    • Have a history of epilepsy or use anti-epileptic drugs for prevention;
    • Received cell therapy within 3 months before screening;
  11. to general anesthesia or stereotactic surgery (such as sleep apnea, , etc.), MRI or PET examinations;
  12. Those with the following abnormalities in the past or detected (if any of the following is met, they will be excluded):

    • Evidence of congestive heart failure or history of end-stage cardiovascular disease;
    • Severe arrhythmias and poorly controlled arrhythmias;
    • abnormalities during the screening or baseline period;
    • History of unstable angina or acute myocardial infarction within the past 3 months;
    • Diabetic patients with poor glycemic control;
    • Hypertensive patients with poorly controlled blood pressure;
  13. Patients with active infection during the screening period (except mild local skin infection) that need antibiotic, antifungal, or antiviral treatment but infection is still not under control;
  14. The presence of severe lung diseases during the screening period;
  15. Patients with uncontrolled diseases;
  16. During the screening period, patients have severe arthritis, limp, severe sequelae of stroke, severe osteoporosis, or history of severe trauma within 1 month, etc., which the investigators assess may affect the evaluations;
  17. Any history of , excluding cured basal cell carcinoma and/or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or ductal carcinoma of the breast;
  18. Serious infectious diseases;
  19. Pregnant or lactating women, women who plan to become pregnant during the study and within 6 months after the end of the study, or women who are unwilling to use effective measures;
  20. Patients who have participated in other clinical studies of drugs or medical devices within 3 months before treatment;
  21. Have a long history of alcoholism or drug abuse;
  22. Patients with a history of severe allergies or allergies to drugs and immunosuppressants;
  23. Any other conditions that the investigator considers unsuitable for participation in the study.
  24. Severe depression
  25. Hallucinations, and hallucinations still exist after optimizing Parkinson's medications
  26. Patients have undergone MRI-guided focused ultrasound thalamotomy
  27. Used immunosuppressants within 3 months, except for the immunosuppressants to be used in this study
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    4.5×10^6 cells / bilateral putamen

    Biological: human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection

  • Experimental
    9.0×10^6 cells / bilateral putamen

    Biological: human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection

  • Experimental
    1.8×10^7 cells / bilateral putamen

    Biological: human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection

  • No intervention
    Standard treatment

Interventions

  • Biologicalhuman allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection

    5.0×10\^7 cells/mL, injection, single dose

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of XS411CN in treatment of primary Parkinson's disease

    To evaluate the safety and tolerability of XS411CN in treatment of primary Parkinson's disease through: 1)The occurrence and incidence of adverse events and serious adverse events (adverse event grading criteria are based on NCI-CTCAE V5.0) 28 days after administration of XS411CN; 2) Changes in vital signs, laboratory tests, 12-lead electrocardiogram, etc. compared with baseline after administration of XS411CN;

    Time frame: 28 days after administration of XS411CN

  2. MDS-UPDRS Part III score during the 'OFF' state

    Change from baseline in MDS-UPDRS Part III (Motor Examination) score during the 'OFF' state at 12 months after administration of XS411 cell injection

    Time frame: Month 12

Secondary outcomes

  1. MDS-UPDRS Part III score during the 'OFF' state

    Change from baseline in MDS-UPDRS Part III (Motor Examination) score during the 'OFF' state at 3 months, 6 months, 9 months after administration of XS411 cell injection

    Time frame: Baseline, Month 3, Month 6, Month 9

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jul 2027, 23 months after the start.

Of 55 phase 1/2 interventional studies under Parkinson Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's planned 23 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Apr 2026 → Jul 2027 and completion Aug 2029 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Jul 23, 2025
StartActual
Aug 5, 2025
Primary completionEst.
Jul 2027was Apr 2026
CompletionEst.
Jul 2028was Aug 2029
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 30, 2026
Primary completion
Apr 30, 2026→Jul 2027
Sep 30, 2026
Study completion
Aug 30, 2029→Jul 2028
Sep 30, 2026
Enrollment
12 (estimated)→39 (actual)
Sep 30, 2026
Interventions
Added Biological: human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection; removed Drug: human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection. Arms added: Standard treatment
Sep 30, 2026
Primary outcomes
1 added
What changed in the outcomes
  • AddedMDS-UPDRS Part III score during the 'OFF' stateTime frame: Month 12
Sep 30, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedMDS-UPDRS Part III score during the 'OFF' stateTime frame: Baseline, Month 3, Month 6, Month 9
Sep 30, 2026
Title
The Safety and Tolerability,Tolerability, Efficacy of XS411CNXS411 Cell Injection infor the Treatment of Primary Parkinson's Disease
Sep 30, 2026
Sponsor
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.→XellSmart Therapeutics (Shanghai) Co., Ltd.
Sep 30, 2026
Design
Added Phase 2
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Recruiting→Active, not recruiting
    Primary completion Apr 30, 2026→Jul 2027
    Study completion Aug 30, 2029→Jul 2028
    Enrollment 12 (estimated)→39 (actual)
    Primary outcomes 1 added
    What changed in the outcomes
    • AddedMDS-UPDRS Part III score during the 'OFF' stateTime frame: Month 12
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedMDS-UPDRS Part III score during the 'OFF' stateTime frame: Baseline, Month 3, Month 6, Month 9
    Interventions Added Biological: human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection; removed Drug: human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection. Arms added: Standard treatment
    Sponsor XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.→XellSmart Therapeutics (Shanghai) Co., Ltd.
    Design Added Phase 2
    Title The Safety and Tolerability,Tolerability, Efficacy of XS411CNXS411 Cell Injection infor the Treatment of Primary Parkinson's Disease
    + 4 other changes: verification date, description, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07080775
Lead sponsor
XellSmart Therapeutics (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Aug 5, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Sep 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion